# A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes

> **NCT04594941** · PHASE2 · COMPLETED · sponsor: **GE Healthcare** · enrollment: 38 (actual)

## Conditions studied

- Coronary Artery Disease (CAD)
- Ischemic Heart Disease

## Interventions

- **DRUG:** Flurpiridaz (18F) Injection

## Key facts

- **NCT ID:** NCT04594941
- **Lead sponsor:** GE Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-27
- **Primary completion:** 2022-05-26
- **Final completion:** 2022-05-26
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04594941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04594941, "A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04594941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*